Risque de thromboembolie veineuse avec les inhibiteurs de Janus kinase : S'agit-il d'un effet de classe ? (Editorial)
Expert Opin Drug Saf. 2022. doi: 10.1080/14740338.2022.2100343
It is too early to conclude that the second-generation JAK inhibitors have a lower VTE risk and caution in patients with VTE risk factors is required.